ALK-Positive
Advertisement
First-Line Lorlatinib Improves Survival and Metastasis in Advanced ALK-Positive Lung Cancer
Rebecca AraujoNon-Small Cell Lung Cancer | November 19, 2020
Early treatment with the anaplastic lymphoma kinase (ALK)-inhibitor lorlatinib reduced cancer progression and death in ...
Read More
FDA Approves New Treatment for ALK-Positive Metastatic NSCLC
Kerri FitzgeraldALK+ NSCLC | November 5, 2018
The U.S. Food and Drug Administration approved lorlatinib for patients with ALK-positive metastatic non-small cell ...
Read More
Advertisement
Advertisement
Latest News

The Accelerated Approval of Telisotuzumab Vedotin for NSCLC: Dr. Singhi Shares What Clinicians Should Know

May 22, 2025

Operating in Oligometastatic Disease: Dr. Antonoff Shares Patient Selection Considerations

May 21, 2025

Lung Cancer Screening: Study Explores Impact of Eligibility Differences by Smoking History

May 20, 2025

Breath Test for Lung Cancer Screening Under Evaluation in Pilot Study

May 19, 2025

Study Highlights Relationship Between Lipid Metabolism, NK Cells in the NSCLC Tumor Microenvironment

May 16, 2025

Medicaid Expansion: Study Investigates Impacts on Lung Cancer Surgery

May 15, 2025

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Contribute

    Our Network

    MashupMD

    Blood Cancers Today

    Cancer Nursing Today

    GU Oncology Now

    Urban Health Today

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |